Clinical trials: Schizophrenia Spectrum
Schizophrenia, Schizoaffective Disorder
Study by Electroencephalography of the Link Between the Lack of Self-compassion and the Disorder of Empathy in Schizophrenia
This research project focuses on a fundamental element of the psychopathology of schizophrenia, that is to say, the disorders of self-awareness and on the functional alterations associated with it, that is to say, self-compassion…
- Trial name
- SCE-SCHIZO (NCT05464563)
- Testing
- Electroencephalogram
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Henri Laborit
Psychosis
Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis
The benefits and harms of antipsychotics are relatively well studied in adults. However, there is a lack of scientifically valid studies regarding the benefits and harms of antipsychotics in children and adolescents with…
- Trial name
- TEA (NCT01119014)
- Testing
- Aripiprazole, Quetiapine
- Where
- 9 sites in Denmark
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anne Katrine Pagsberg
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of two dosages of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute episode of schizoaffective disorder.
- Trial name
- NCT00397033
- Testing
- Paliperidone ER
- Volunteers
- 316 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia; Psychosis
Evaluating a Novel Mobile App for Social Cognition in Psychosis
To develop, and then evaluate a mobile phone app to deliver therapy homework activities between group sessions (social cognition intervention) in individuals with psychosis.
- Trial name
- NCT04260763
- Testing
- Social Cognition Group, Novel Mobile App
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- King's College London
Schizophrenia, Schizo Affective Disorder
Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)
To characterize the real-life clinical use of AOM in a hospitalized patient population with schizophrenia, schizoaffective disorder or BP1 requiring LAI therapy and evaluate its short-term effectiveness associated with its…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
- Trial name
- INITIATE (NCT04907279)
- Testing
- Aripiprazole Once-Monthly (AOM)
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Otsuka Canada Pharmaceutical Inc.
Schizophrenia
Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse
This is a prospective, non-interventional, multicentre study designed to collect information about the effectiveness, safety and tolerability of Risperidone ISM in patients diagnosed with schizophrenia who are suffering an acute…
- Trial name
- RESHAPE (NCT05480046)
- Testing
- Risperidone ISM
- Where
- 77 sites in Germany, Italy and 3 more
- Volunteers
- 275 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Schizophrenia
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
The purpose of the study is to evaluate the efficacy, safety, and tolerability of different dose regimens of TV-46000 administered subcutaneously (SC) as compared to placebo during maintenance treatment in adult and adolescent…
- Trial name
- RISE (NCT03503318)
- Testing
- TV-46000
- Where
- 81 sites in United States, Bulgaria
- Volunteers
- 544 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Schizophrenia, Psychosis
Optimizing Cognitive Remediation Outcomes in Schizophrenia
The purpose of this study is to drive an optimal response to neuroplasticity-based cognitive remediation in schizophrenia in order to maximize treatment response.
- Trial name
- CAST (NCT02105779)
- Testing
- Targeted Cognitive Training, Social Cognitive Training
- Where
- United States
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Schizophrenia
Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes
Schizophrenia has long been known to be an illness with significant evidence for a genetic predisposition. The purpose of this study is to determine the genetic abnormalities that cause childhood and adult onset schizophrenia.
- Trial name
- NCT00108303
- Testing
- Diagnostic
- Where
- United States
- Volunteers
- 538 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Schizophrenia
The Significance of Deviation in Time From the 12-hour Standard Serum-clozapine Monitoring.
The role of Therapeutic Drug Monitoring (TDM) in clozapine dose adjustment have been debated. Blood samples for s-clozapine monitoring should be drawn 12 hours post dose.
- Trial name
- NCT02625103
- Testing
- Blood sampling, Clozapine
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Schizophrenia, Treatment-resistant Schizophrenia
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
SchizOMICS is a Phase IV, multicenter, dose-flexible, open-label, randomized controlled clinical trial to evaluate the efficacy and safety of aripiprazole versus paliperidone using multi-omics data in patients with a first…
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders
- Trial name
- SchizOMICS (NCT06060886)
- Testing
- Aripiprazole, Paliperidone
- Volunteers
- 244 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Schizophrenia
Switching From Consta® to Sustenna® in Patients With Schizophrenia
The aim of this study is observation of effectiveness and side effect of patients with schizophrenia who will switch the antipsychotics from risperidone long acting injection to paliperidone palmitate.
- Trial name
- NCT01698216
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Seoul National University Hospital
Schizophrenia
Effects of Cognitive Remediation Therapy on Schizophrenia Patients Through Functional Magnetic Resonance Imaging
Cognitive Remediation Therapy (CRT) can enhance cognitive performance in patients with schizophrenia improving clinical outcome. However, the neurobiological mechanism underlying cognitive improvement is not well understood.
- Trial name
- NCT01318850
- Testing
- Cognitive Remediation Therapy, Psychoeducation, Healthy controls
- Where
- Spain
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Schizophrenia
Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119
This study will consist of 2 parts: Part Ⅰ-in healthy adult subjects, Part Ⅱ-in adult patients with schizophrenia
- Trial name
- NCT06504290
- Testing
- VV119 （in healthy adult subjects）, VV119(in adult patients with schizophrenia)
- Where
- 4 sites in China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Schizophrenia
A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia
A study to evaluate the efficacy and safety of an experimental drug (SEP-363856) in acutely psychotic adults with schizophrenia
- Trial name
- NCT02969382
- Testing
- SEP-363856
- Where
- 33 sites in United States, Hungary and 3 more
- Volunteers
- 245 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Comparing Cognitive Remediation Approaches for Schizophrenia
This research compares the relative efficacy of two empirically-supported, standardized programs of cognitive remediation for treatment of cognitive deficits and community function in schizophrenia to help inform best practices.
- Trial name
- NCT04123223
- Testing
- Cognitive Remediation, Computer Games
- Where
- 2 sites in United States
- Volunteers
- 135 people
- Sponsor
- Wesleyan University
Chromosome 22q11.2 Deletion Syndrome
Genetics and Psychopathology in the 22q11 Deletion Syndrome
The purposes of this study are to: 1. study the nature and longitudinal course of psychiatric symptoms in children with the 22q11.2 deletion syndrome and 2. identify genes that contribute to the occurrence of these symptoms.
- Trial name
- NCT00161109
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht
Schizophrenia
A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia
To investigate the efficacy and safety of OPC-34712 in comparison with placebo in patients with schizophrenia.
- Trial name
- NCT01451164
- Testing
- OPC-34712
- Where
- Japan
- Volunteers
- 459 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia, Obesity
Metformin for Weight Loss in Schizophrenia
Study hypothesis is that patients on antipsychotics medication treated with metformin will show loss in weight and improved measures of glucose metabolism.
- Trial name
- NCT01177709
- Testing
- Metformin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia
Validation of a Scale to Evaluate the Perception of Oral Health in Patients With Schizophrenia
Apart from objective criteria for the evaluation of oral health (CAO, CPI…), there are no scales to evaluate the oral health of patients with schizophrenia.
- Trial name
- QUALITY (NCT02730832)
- Testing
- Questionnaires completed at D0, Questionnaires completed at D15 (test-retest for 30 patients)
- Where
- France
- Volunteers
- 59 people
- Sponsor
- Centre Hospitalier Universitaire Dijon